Roberto Galli

Director of Finance/CFO at NEWRON PHARMACEUTICALS S.P.A.

Commercial Services

Health Technology

Consumer Services

Profile

Roberto Galli currently works at Newron Sweden AB, as Director, Newron Pharmaceuticals US, Inc., as Secretary, Treasurer & Director, and Newron Pharmaceuticals SpA, as Chief Financial Officer from 2023.
Mr. Galli also formerly worked at PricewaterhouseCoopers SpA, as Senior Auditor from 1996 to 2002 and Coopers & Lybrand SpA, as Auditor.
Mr. Galli received his undergraduate degree from the University of Bocconi.

Roberto Galli active positions

Companies	Position	Start
NEWRON PHARMACEUTICALS S.P.A.	Director of Finance/CFO	2011-12-31
Newron Sweden AB Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders	Director/Board Member	-
Newron Pharmaceuticals US, Inc. Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease.	Director/Board Member	-

All active positions of Roberto Galli

Former positions of Roberto Galli

Companies	Position	End
PricewaterhouseCoopers SpA PricewaterhouseCoopers SpA Miscellaneous Commercial ServicesCommercial Services Provides audit, assurance, tax and consulting services	Corporate Officer/Principal	2002-09-30
Coopers & Lybrand SpA Coopers & Lybrand SpA Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Coopers & Lybrand SpA is an Italian company.	Comptroller/Controller/Auditor	-

See the detail of Roberto Galli's experience

Training of Roberto Galli

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Roberto Galli's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	6
Newron Pharmaceuticals SpA Newron Pharmaceuticals SpA Pharmaceuticals: MajorHealth Technology Develops and sells novel therapies central & peripheral nervous system	Health Technology
Newron Sweden AB Newron Sweden AB Pharmaceuticals: MajorHealth Technology Develops and manufactures therapeutic drugs for central nervous system disorders	Health Technology
University of Bocconi University of Bocconi Other Consumer ServicesConsumer Services Functions as a College/University	Consumer Services
PricewaterhouseCoopers SpA PricewaterhouseCoopers SpA Miscellaneous Commercial ServicesCommercial Services Provides audit, assurance, tax and consulting services	Commercial Services
Coopers & Lybrand SpA Coopers & Lybrand SpA Miscellaneous Commercial ServicesCommercial Services Part of PricewaterhouseCoopers International Ltd., Coopers & Lybrand SpA is an Italian company.	Commercial Services
Newron Pharmaceuticals US, Inc. Newron Pharmaceuticals US, Inc. Miscellaneous Commercial ServicesCommercial Services The company is based in Wilmington, DE. The company’s lead product candidate, evenamide, is an oral glutamate modulator in phase III trials as an add-on therapy for treatment-resistant and chronic schizophrenia. Newron also markets Xadago® (safinamide), a selective MAO-B inhibitor approved for Parkinson’s disease treatment in over 20 countries, and is developing ralfinamide for orphan neuropathic pain. Founded in 1999, Newron Pharmaceuticals US, Inc. is a biopharmaceutical company specializing in the development of novel therapies for central and peripheral nervous system diseases, including treatment-resistant schizophrenia and Parkinson’s disease.	Commercial Services